Prelude Therapeutics
Headquarters country
United States
Registry sponsor category
Industry
- Company name
- Prelude Therapeutics
- Organisation type
- Industry
- Registered legal name
- Prelude Therapeutics Inc
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Prelude Therapeutics
- Prelude Therapeutics Incorporated
- Headquarters country
- United States
- Publicly traded (proxy)
- Yes
- Listing at source
- Listed
- SEC filer number (CIK)
- 0001678660
Related records
Trials (13)
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
- A Study of PRT1419 in Patients With Advanced Solid Tumors
- A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
- A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- A Study of PRT2527 in Participants With Advanced Solid Tumors
- A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
- A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation